Physician profile
Jacob Diskin
NPI 1871053751
$5,072.22
in general payments reported to CMS, 2019-2025
23 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what 78% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $155 · 2021: $2,036 · 2022: $514 · 2023: $762 · 2024: $563 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,332 · Entertainment: $30.39 · Education: $4.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,331.88 |
| Entertainment | $30.39 |
| Education | $4.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $1,997.68 | 2020-2021 | |
| Alcon Vision LLC | $556.44 | 2021-2025 | Tryptyr, Clareon |
| Bausch & Lomb Americas INC. | $426.94 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| New World Medical,INC. | $325.92 | 2023 | |
| Glaukos Corporation | $216.52 | 2022-2025 | Istent Infinite, Idosetr |
| Abbvie INC. | $205.15 | 2022-2025 | |
| Biotissue Holdings INC. | $200.67 | 2022-2025 | |
| Amgen INC. | $157.03 | 2025 | Tepezza |
| Sight Sciences, INC. | $142.11 | 2023-2024 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $109.75 | 2022-2023 | Catalys System, Tecnis Iol |
| Tarsus Pharmaceuticals, INC. | $105.31 | 2024-2025 | Xdemvy |
| Allergan, INC. | $99.99 | 2020 | |
| Oyster Point Pharma, INC. | $84.06 | 2024-2025 | Tyrvaya, Ryzumvi |
| Ocular Therapeutix, INC. | $80.93 | 2023-2024 | Dextenza |
| Novartis Pharmaceuticals Corporation | $77.60 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $76.79 | 2024-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $76.40 | 2024-2025 | |
| Optos, INC. | $30.39 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Rayner Intraocular Lenses Limited | $27.25 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $23.55 | 2024 | |
| Harrow Eye, LLC | $20.72 | 2025 | Vevye |
| Thea Pharma INC. | $16.37 | 2025 | Iyuzeh |
| Beaver-Visitec International, INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacob Diskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.